Figure 3.
The effect of including the hepatic sinusoidal efflux transporter MRP4 with the intravenous dose of rosuvastatin (a) vs. removing MRP4 involvement in M‐III (b) and the effect of including intestinal apical uptake with the 40 mg oral dose of rosuvastatin (c) vs. removing the apical uptake (d) in M‐III. AUC, area under the concentration‐time curve; Cmax, maximum concentration; hr, hour; i.v., intravenous; MRP, multidrug resistance protein; tmax, time to reach maximum concentration.